Kristi Rosa
Associate Editorial Director at OncLive
associate editorial director for @OncLive. bibliophile. cat mom. tweets are my own.
Articles
-
6 days ago |
onclive.com | Kristi Rosa
Welcome to OncLive®’s OncFive!Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.
-
6 days ago |
oncnursingnews.com | Kristi Rosa
April 18, 2025Fact checked by Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib.
-
1 week ago |
onclive.com | Kristi Rosa
Frontline treatment with dasatinib (Sprycel) followed by sequential CAR T-cell therapy and maintenance dasatinib monotherapy elicited responses with acceptable safety in patients with newly diagnosed Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL), according to data from a nonrandomized phase 2 study (NCT04788472) published in JAMA Oncology.1 All 28 patients completed 2-week induction treatment with vindesine, dexamethasone, and continuous dasatinib at 100 mg daily...
-
1 week ago |
curetoday.com | Kristi Rosa
While the addition of Nubeqa (darolutamide) to androgen deprivation therapy proved clinically beneficial among patients with metastatic hormone-sensitive prostate cancer, the nurse’s role in educating patients on its effect and its safety is key, according to Brenda Martone, registered nurse and advanced practice provider.
-
1 week ago |
onclive.com | Kristi Rosa
The addition of subcutaneous daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) demonstrated consistent clinical benefit without any detriment to health-related quality of life (HRQOL) vs VRd alone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma enrolled in the phase 3 CEPHEUS trial (NCT03652064), supporting the use of the quadruplet therapy in those able to receive bortezomib.1 The data, which were shared...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 435
- Tweets
- 1K
- DMs Open
- No
RT @OncLive: Happy International Women’s Day! 💜 A heartfelt thank you to the incredible panel of women who led the 2nd Annual Women in Onco…
RT @OncLive: 🚨 Takeover Alert! 🚨 This #InternationalWomensDay, we're handing over the mic to 2 powerhouse female oncologists: @heMEGirl_MD…
RT @OncLive: It's time for this week's #OncFive 5️⃣, our top 5 articles in #oncology. Check it out: https://t.co/q8uKNj3ABG https://t.co/AM…
